Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af KT-621 administreret oralt til voksne deltagere med moderat til svær eosinofil astma (BREADTH)

2. oktober 2026 opdateret af: Kymera Therapeutics, Inc.

En fase 2b, randomiseret, dobbeltblind, placebo-kontrolleret, parallel-gruppe, multicentret, dosisundersøgende undersøgelse af effektiviteten og sikkerhedsprofilen for KT-621 administreret oralt til voksne deltagere med ukontrolleret moderat til svær eosinofil astma

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.

The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

264

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • Concepción del Uruguay, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • Lobos, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • Mar del Plata, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • Quilmes, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • Rosario, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • San Miguel de Tucumán, Argentina
        • Rekruttering
        • Kymera Investigative Site
      • Brussels, Belgien
        • Rekruttering
        • Kymera Investigative Site
      • Erpent, Belgien
        • Rekruttering
        • Kymera Investigative Site
      • Ghent, Belgien
        • Rekruttering
        • Kymera Investigative Site
      • Liège, Belgien
        • Rekruttering
        • Kymera Investigative Site
      • Bedford, Det Forenede Kongerige, MK40 2FG
        • Rekruttering
        • Kymera Investigative Site
      • Birmingham, Det Forenede Kongerige
        • Rekruttering
        • Kymera Investigative Site
      • Bristol, Det Forenede Kongerige
        • Rekruttering
        • Kymera Investigative Site
      • Leicester, Det Forenede Kongerige
        • Rekruttering
        • Kymera Investigative Site
      • London, Det Forenede Kongerige
        • Rekruttering
        • Kymera Investigative Site
      • Wythenshawe, Det Forenede Kongerige
        • Rekruttering
        • Kymera Investigative Site
    • California
      • Lancaster, California, Forenede Stater, 93534
        • Rekruttering
        • Kymera Investigative Site
      • Long Beach, California, Forenede Stater, 90815
        • Rekruttering
        • Kymera Investigative Site
      • Northridge, California, Forenede Stater, 91324
        • Rekruttering
        • Kymera Investigative Site
      • Redding, California, Forenede Stater, 96001
        • Rekruttering
        • Kymera Investigative Site
      • San Francisco, California, Forenede Stater, 94112
        • Rekruttering
        • Kymera Investigative Site
      • Upland, California, Forenede Stater, 91786
        • Rekruttering
        • Kymera Investigative Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • Kymera Investigative Site
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Rekruttering
        • Kymera Investigative Site
    • Florida
      • Loxahatchee Groves, Florida, Forenede Stater, 33470
        • Rekruttering
        • Kymera Investigative Site
      • Miami, Florida, Forenede Stater, 33126
        • Rekruttering
        • Kymera Investigative Site
      • Miami, Florida, Forenede Stater, 33173
        • Rekruttering
        • Kymera Investigative Site
      • Miami Lakes, Florida, Forenede Stater, 33014
        • Rekruttering
        • Kymera Investigative Site
      • Orlando, Florida, Forenede Stater, 32819
        • Rekruttering
        • Kymera Investigative Site
      • Tampa, Florida, Forenede Stater, 33607
        • Rekruttering
        • Kymera Investigative Site
    • Georgia
      • East Point, Georgia, Forenede Stater, 30344
        • Rekruttering
        • Kymera Investigative Site
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • Kymera Investigative Site
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • Kymera Investigative Site
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40217
        • Rekruttering
        • Kymera Investigative Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Kymera Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27517
        • Rekruttering
        • Kymera Investigative Site
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Kymera Investigative Site
    • Ohio
      • Toledo, Ohio, Forenede Stater, 43617
        • Rekruttering
        • Kymera Investigative Site
    • Oklahoma
      • Edmond, Oklahoma, Forenede Stater, 73034
        • Rekruttering
        • Kymera Investigative Site
    • Oregon
      • Clackamas, Oregon, Forenede Stater, 97015
        • Rekruttering
        • Kymera Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
        • Rekruttering
        • Kymera Investigative Site
      • Pittsburgh, Pennsylvania, Forenede Stater, 15241
        • Rekruttering
        • Kymera Investigative Site
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • Kymera Investigative Site
    • South Carolina
      • North Charleston, South Carolina, Forenede Stater, 29406
        • Rekruttering
        • Kymera Investigative Site
      • Rock Hill, South Carolina, Forenede Stater, 29732
        • Rekruttering
        • Kymera Investigative Site
    • Tennessee
      • Chattanooga, Tennessee, Forenede Stater, 37403
        • Rekruttering
        • Kymera Investigative Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75209
        • Rekruttering
        • Kymera Investigative Site
      • Dallas, Texas, Forenede Stater, 75246
        • Rekruttering
        • Kymera Investigative Site
      • McKinney, Texas, Forenede Stater, 75069
        • Rekruttering
        • Kymera Investigative Site
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • Kymera Investigative Site
      • Rome, Italien
        • Rekruttering
        • Kymera Investigative Site
      • Bialystok, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Gdansk, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Lodz, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Poznan, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Sosnowiec, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Tarnów, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Trzebnica, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Wroclaw, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Zawadzkie, Polen
        • Rekruttering
        • Kymera Investigative Site
      • Brasov, Rumænien
        • Rekruttering
        • Kymera Investigative Site
      • Craiova, Rumænien
        • Rekruttering
        • Kymera Investigative Site
      • Timișoara, Rumænien
        • Rekruttering
        • Kymera Investigative Site
      • Belgrade, Serbien, 11000
        • Rekruttering
        • Kymera Investigative Site
      • Belgrade, Serbien
        • Rekruttering
        • Kymera Investigative Site
      • Kamenitz, Serbien, 21204
        • Rekruttering
        • Kymera Investigative Site
      • Užice, Serbien, 31000
        • Rekruttering
        • Kymera Investigative Site
      • Bardejov, Slovakiet
        • Rekruttering
        • Kymera Investigative Site
      • Košice, Slovakiet
        • Rekruttering
        • Kymera Investigative Site
      • Spišská Nová Ves, Slovakiet
        • Rekruttering
        • Kymera Investigative Site
      • Cadiz, Spanien
        • Rekruttering
        • Kymera Investigative Site
      • Jerez de la Frontera, Spanien
        • Rekruttering
        • Kymera Investigative Site
      • Madrid, Spanien
        • Rekruttering
        • Kymera Investigative Site
      • Mataró, Spanien
        • Rekruttering
        • Kymera Investigative Site
      • Santander, Spanien
        • Rekruttering
        • Kymera Investigative Site
      • Gyeonggi-do, Sydkorea
        • Rekruttering
        • Kymera Investigative Site
      • Seoul, Sydkorea
        • Rekruttering
        • Kymera Investigative Site
      • Berlin, Tyskland
        • Rekruttering
        • Kymera Investigative Site
      • Leipzig, Tyskland
        • Rekruttering
        • Kymera Investigative Site
      • Vienna, Østrig
        • Rekruttering
        • Kymera Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.
  • Must have a physician diagnosis of asthma for at least 1 year prior to the Screening visit.
  • Must be on a stable regimen of medium- to high- dose inhaled corticosteroid (ICS), in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medications used for at least 12 weeks, at a stable dose and regimen, with no change in the dose or frequency of administration for at least 4 weeks prior to the Screening visit and between the Screening and Baseline visits.
  • Must have a pre-bronchodilator FEV1 40 to 80% of predicted normal at the Screening and Baseline visits, prior to randomization.
  • Must have an ACQ-5 score ≥ 1.5 at the Screening and Baseline visits, prior to randomization.
  • Must have a FeNO level of ≥ 25 ppb at the Screening and Baseline visits.
  • Must have a demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL at Screening.
  • Must have an absolute blood eosinophil count must be ≥ 0.30 × 10^9/L at Screening.
  • Must have a documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening.
  • Must agree to contraceptive requirements in compliance with the clinical study and local requirements.
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.

Exclusion Criteria:

  • Must not have any clinically significant pulmonary disease other than asthma.
  • Must not have had an asthma exacerbation, requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit up to and including the Baseline visit.
  • Must not have any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and/or study procedures.
  • Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
  • Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
  • Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
  • Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
  • Must not be a current smoker of nicotine/tobacco as well as non-nicotine products, have a smoking history of ≥ 10 pack years, or use vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit.
  • Must not have a known sensitivity to any of the components of KT-621.
  • Must not be a member of the investigational team or his/her immediate family.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Gruppe 1: KT-621 Dosis 1

Oral drug

Eksperimentel: Gruppe 2: KT-621 Dosis 2

Oral drug

Eksperimentel: Gruppe 3: KT-621 Dosis 3

Oral drug

Placebo komparator: Gruppe 4: Placebo

Oral placebo matched to KT-621

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Ændring fra baseline i præ-bronkodilator FEV1
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12

Sekundære resultatmål

Resultatmål
Tidsramme
Ændring fra baseline i post-bronkodilator FEV1
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12
Ændring fra baseline i Asthma Control Questionnaire 5-spørgsmålsversion (ACQ-5) score
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12
Ændring fra baseline i Standardiseret Astma Livskvalitets Spørgeskema [AQLQ(S)] Global Score
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12
Hyppighed af behandlingsrelaterede bivirkninger (TEAEs)
Tidsramme: Fra baseline gennem uge 16
Fra baseline gennem uge 16
Hyppigheden af behandlingsrelaterede alvorlige bivirkninger (SAE'er)
Tidsramme: Fra baseline gennem uge 16
Fra baseline gennem uge 16
Plasmakoncentration af KT-621 afledt fra plasmakoncentrationstidsdata
Tidsramme: Fra baseline til uge 16
Fra baseline til uge 16

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. januar 2026

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

6. januar 2026

Først indsendt, der opfyldte QC-kriterier

6. januar 2026

Først opslået (Faktiske)

7. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. oktober 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • KT621-AS-202

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .